Skip to main content
Erschienen in: Medical Oncology 2/2011

01.06.2011 | Original Paper

Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation

verfasst von: Vallian Sadeq, Nassiri Isar, Tavassoli Manoochehr

Erschienen in: Medical Oncology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

PTEN/MMAC1/TEP1 encodes a tumor suppressor protein, which regulates cell cycle progression, translation, and apoptosis by blocking the activation of Akt/PKB. The loss of PTEN function increases cell survival and induces tumor invasion. In this study, PTEN promoter status and its correlation with genetic and pathologic parameters were analyzed in genomic DNA from Iranian patients with breast cancer. DNA methylation patterns in the CpG islands were determined by a methylation-specific PCR (MSP) assay. PTEN promoter methylation was found to be present in 37 of 53(70%) tumor tissues and none in 20 normal counterparts. Moreover, promoter methylation was found in patients with heterozygote mutation in the PTEN gene. The pathological history of cancerous tissue sections showed that PTEN gene could be inactivated at the stages III and IV in sporadic breast cancer. These findings suggested that promoter hypermethylation of PTEN might contribute to the progression of sporadic breast cancer in human.
Literatur
1.
Zurück zum Zitat Stambolic V, Suzuki A, Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39.PubMedCrossRef Stambolic V, Suzuki A, Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39.PubMedCrossRef
2.
Zurück zum Zitat Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol. 1999;146:389–403.PubMedCrossRef Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol. 1999;146:389–403.PubMedCrossRef
3.
Zurück zum Zitat Freeman DJ, Li AG, Wei G, Li H-H, Kertesz N, Lesche R, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3:117–30.PubMedCrossRef Freeman DJ, Li AG, Wei G, Li H-H, Kertesz N, Lesche R, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3:117–30.PubMedCrossRef
4.
Zurück zum Zitat Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23:575–87.PubMedCrossRef Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23:575–87.PubMedCrossRef
5.
Zurück zum Zitat Reifenberger J, Wolter M, Bostrom J, et al. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch. 2000;436:487–93.PubMedCrossRef Reifenberger J, Wolter M, Bostrom J, et al. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch. 2000;436:487–93.PubMedCrossRef
6.
Zurück zum Zitat Piekarski JH, Biernat W. Clinical significance of CK5/6 and PTEN protein expression in patients with bilateral breast carcinoma. Histopathology. 2006;49:248–55.PubMedCrossRef Piekarski JH, Biernat W. Clinical significance of CK5/6 and PTEN protein expression in patients with bilateral breast carcinoma. Histopathology. 2006;49:248–55.PubMedCrossRef
7.
Zurück zum Zitat Li Z, Wings TY, Chow LWC. PTEN and VEGF: possible predictors for sentinel lymph node micro-metastasis in breast cancer. Biomed Pharmacother. 2007;61:558–61.CrossRef Li Z, Wings TY, Chow LWC. PTEN and VEGF: possible predictors for sentinel lymph node micro-metastasis in breast cancer. Biomed Pharmacother. 2007;61:558–61.CrossRef
8.
Zurück zum Zitat Mise-Omataa S, Obataa Y, Iwaseb S, Misec N, Doia T. Transient strong reduction of PTEN expression by specific RNAi induces loss of adhesion of the cells. Biochem Biophys Res. 2005;38:1034–42.CrossRef Mise-Omataa S, Obataa Y, Iwaseb S, Misec N, Doia T. Transient strong reduction of PTEN expression by specific RNAi induces loss of adhesion of the cells. Biochem Biophys Res. 2005;38:1034–42.CrossRef
9.
Zurück zum Zitat Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten±mice. Cancer Res. 2000;60(13):3605–11.PubMed Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten±mice. Cancer Res. 2000;60(13):3605–11.PubMed
10.
Zurück zum Zitat Nassiri I, Tavasoli M, Faghihi M. Pharmacogenomic profiling of the PI3 K/PTEN pathway in sporadic breast cancer. Iran Biomed J. 2008;12(4):209–14. Nassiri I, Tavasoli M, Faghihi M. Pharmacogenomic profiling of the PI3 K/PTEN pathway in sporadic breast cancer. Iran Biomed J. 2008;12(4):209–14.
11.
Zurück zum Zitat Nassiri I, Tavasoli M, Faghihi M. Mutational analysis in the MMAC1 gene associated in patients with juvenile polyposis syndrome and cowden fisease. Austral Asian J Can. 2008;7(3):25–30. Nassiri I, Tavasoli M, Faghihi M. Mutational analysis in the MMAC1 gene associated in patients with juvenile polyposis syndrome and cowden fisease. Austral Asian J Can. 2008;7(3):25–30.
12.
Zurück zum Zitat Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot. 1975;28:727–32.PubMed Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot. 1975;28:727–32.PubMed
13.
Zurück zum Zitat Singer C, Köstler W, Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies. Biochim Biophys Acta. 2008;1786(2):105–13.PubMed Singer C, Köstler W, Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies. Biochim Biophys Acta. 2008;1786(2):105–13.PubMed
14.
Zurück zum Zitat Sambrook J, Fritsh EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 2001. Sambrook J, Fritsh EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 2001.
15.
Zurück zum Zitat Miller SA, Dykes DD, Polesky HF. A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.PubMedCrossRef Miller SA, Dykes DD, Polesky HF. A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.PubMedCrossRef
16.
Zurück zum Zitat Zysman MA, Chapman WB, Bharati B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol. 2002;160:795–800.PubMedCrossRef Zysman MA, Chapman WB, Bharati B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol. 2002;160:795–800.PubMedCrossRef
18.
Zurück zum Zitat Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol. 2002;33:405–9.PubMedCrossRef Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol. 2002;33:405–9.PubMedCrossRef
19.
Zurück zum Zitat Khan K, Umagal K, Vora J, Bose N, Sehgal S, Koeffler E, et al. PTEN promoter is methylated in a proportion of invasive breast cancer. Int J Cancer. 2004;112:407–10.PubMedCrossRef Khan K, Umagal K, Vora J, Bose N, Sehgal S, Koeffler E, et al. PTEN promoter is methylated in a proportion of invasive breast cancer. Int J Cancer. 2004;112:407–10.PubMedCrossRef
20.
Zurück zum Zitat Kang Y, Lee HS, Ho KW. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest. 2002;82:285–91.PubMed Kang Y, Lee HS, Ho KW. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest. 2002;82:285–91.PubMed
21.
Zurück zum Zitat Chang S, Lee SN, Cho MS, Koo H, Han WS, Im SA, et al. Loss of PTEN expression in breast cancers. Korean J Path. 2005;39:236–41. Chang S, Lee SN, Cho MS, Koo H, Han WS, Im SA, et al. Loss of PTEN expression in breast cancers. Korean J Path. 2005;39:236–41.
Metadaten
Titel
Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation
verfasst von
Vallian Sadeq
Nassiri Isar
Tavassoli Manoochehr
Publikationsdatum
01.06.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9473-8

Weitere Artikel der Ausgabe 2/2011

Medical Oncology 2/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.